Concord Biotech

Incorporated in 1984, Concord Biotech is engaged in research, development, manufacturing, and sale of pharmaceutical products, offering biopharmaceutical APIs (active pharmaceuticals ingredients) and formulations across therapeutic areas such as immunosuppressants, oncology, anti-infectives, nephrology, and critical care. The company operates through three business verticals: APIs, finished formulations, and contract research & manufacturing. In the API segment, the company works with various global formulation manufacturers to supply APIs for immunosuppressants, oncology, and anti-infective therapies. Its finished formulations serves B2B and B2C channels, including government and corporate hospitals as well as end patients. Additionally, the company works with several global biopharmaceutical companies in the areas of fermentation, semi-synthetic APIs and finished formulations. The company has its pan India presence along with 70+ countries globally. Concord Biotech Limited was originally incorporated as `Servomed Pharmaceuticals Private Limited' at Ahmedabad, Gujarat as a Private Limited Company dated November 23, 1984, issued by the Registrar of Companies. Thereafter, name of the Company was changed to `Concord Biotech Limited' dated February 16, 2001, which became a Public Company and a fresh Certificate of Incorporation dated November 7, 2001 was issued by the RoC. The Company is an India-based bio pharma and one of the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology in terms of market share, based on volume in supplying to over 70 countries including regulated markets, such as the United States, Europe and Japan, and India. Presently, it is engaged in research and development, manufacturing, marketing and selling of pharmaceutical products. Its API manufacturing facilities are located at Dholka and Limbasi, and formulations facility at Valthera in Gujarat. In 2000, the Company was acquired by the Promoter, Mr. Sudhir Vaid. In 2016, the Company launched formulation business in India as well as emerging markets, including Nepal, Mexico, Indonesia, Thailand, Ecuador, Kenya, Singapore and Paraguay, and have further expanded to the United States. It established a facility at Valthera, Gujarat. It set up a joint venture in Japan to grow business in 2018. In 2019, the Company received two ANDA approvals. It expanded their business into critical care segment in India. It commenced marketing of Mycophenolate Mofetil Capsules USP 250 mg. In 2020, Mycophenolate Sodium Tablets got launched in the US market. The Company introduced a new manufacturing unit at Limbasi, and commenced operations in July, 2021. As of March 31, 2022, the Company had 6 fermentation-based immunosuppressant APIs, including tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus and pimecrolimus. It had 3 manufacturing facilities in the state of Gujarat, India, comprising API manufacturing facilities in Dholka and Limbasi and a formulation manufacturing facility in Valthera, which were commercialized in 2000, 2021 and 2016, respectively. Their total annual installed fermentation capacity for APIs was 1,250 m3, as of March 31, 2022. It had a total of 41 manufacturing blocks and 387 reactors in the Dholka and Limbasi facilities. In August 2023, Company made an Initial Public Offer by issuing 20,925,652 Equity Shares aggregating to Rs 1551 Crores through Offer for Sale. The Company launched 21 new formulations products in 2025.